Neuronic and Santa Clara University partner to develop next-gen neurotech for photobiomodulation guided by real-time brain activity
May 11, 2023 12:00 ET
|
Neuronic Devices Operations GmbH
Integrating photobiomodulation with neurofeedback will revolutionize treatment of brain disorders SANTA CLARA, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Neuronic, a multi-national company focused...
National Institutes of Health Awards Grant for Pivotal Clinical Trial of gammaCore™ (nVNS) in Patients with Opioid Use Disorders
April 26, 2023 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the National Institute on...
Study Presented at 75th Annual Meeting of the American Academy of Neurology Demonstrates that gammaCore (nVNS) Can Accelerate Foreign Language Learning
April 24, 2023 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., April 24, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the Air Force Research...
electroCore, Inc. Announces Product Registration in Indonesia, Malaysia and South Africa
April 06, 2023 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., April 06, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the receipt of a...
electroCore, Inc. Announces gammaCore Non-Invasive Vagus Nerve Stimulator Available Through the Carrick Institute
April 04, 2023 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the...
electroCore Reports Results of Pre-Clinical Trial in a Model of Traumatic Brain Injury
March 23, 2023 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., March 23, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of a paper...
electroCore's Truvaga Users Reported Improved Stress, Anxiety, Sleep, Energy and Mood in Recent Focus Group Study
March 21, 2023 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., March 21, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the results of a...
electroCore Affirms No Direct Exposure to Silicon Valley Bank, Silvergate Bank, or Signature Bank
March 14, 2023 08:30 ET
|
electroCore, Inc.
ROCKAWAY, N.J., March 14, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today it does not have direct exposure...
Healthcare Bioconvergence Global Market Report 2022: Sector to Reach $215.2 Billion by 2030 at a CAGR of 7.4%
March 13, 2023 11:38 ET
|
Research and Markets
Dublin, March 13, 2023 (GLOBE NEWSWIRE) -- The "Healthcare Bioconvergence Market Size, Share & Trends Analysis Report By Application (Drug Discovery, Regenerative Medicine, Bioelectronics), By...
electroCore Announces Poster to be Presented at the 2023 American Academy of Neurology Annual Scientific Meeting
March 13, 2023 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., March 13, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that data from a sham controlled...